A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
Follicular Lymphoma|Marginal Zone Lymphoma
BIOLOGICAL: EO2463|DRUG: lenalidomide|BIOLOGICAL: rituximab
Phase 1: Recommended Phase 2 Dose | Adverse Events Assessment |, Incidences of adverse events, Treatment-Emergent Adverse events, Serious Adverse Events, Deaths, and Laboratory Abnormalities Using the National Cancer Institute-Common Terminology Criteria for Adverse events (NCI-CTCAE) V5.0., Up to 24 months|Phase 2: Overall Response Rate, Overall Response Rate According to the Lugano Classification 2014 during EO2463 Monotherapy, Up to 24 months
Safety and Tolerability for EO2463 Administered as Monotherapy and in Combination with Lenalidomide, Rituximab and Lenalidomide/Rituximab, Incidences Of Adverse Events, Treatment-Emergent Adverse events, Serious Adverse events, Deaths, Treatment Discontinuations/Delays, And Laboratory Abnormalities Using The NCI-CTCAE V5.0 Grading System, Up to 24 months|Assessment of the Immunogenicity in Relation to OMP72, OMP64, OMP65, OMP66, and UCP2 that Compose EO2463, Immunogenicity will be assessed by interferon-Gamma (IFN-Î“) enzyme-Linked immunospot , and by intracellular cytokines staining, and multimers staining assays, Up to 24 months|Overall Response Rate, Overall Response Rate as described by the Lugano Classification 2014, and by the Lymphoma Response to Immunomodulatory Therapy Criteria (Lyric) 2016 by trial cohort, Up to 24 months|Duration of response, Duration of Response as described by the Lugano Classification 2014, and by the Lymphoma Response to Immunomodulatory Therapy Criteria (Lyric) 2016 by trial cohort, Up to 7 years after last patient enrolled|Evaluation of Overall Survival, The time interval from the date of first study treatment administration to the date of death due to any cause, Up to 7 years after last patient enrolled
EO2463 Is an innovative cancer peptide therapeutic vaccine based on the homologies between tumor associated antigens and microbiome-derived peptides that will be administered alone and in combination with lenalidomide, rituximab, and lenalidomide/rituximab to generate safety and preliminary efficacy data in patients with indolent NHL